Last reviewed · How we verify
NCT05499169: COACH
Coach Pilot Study: Assessing Cognitive Function and Related Small Vessel Disease Markers After Intracerebral Hemorrhage
trial in Cerebral Amyloid Angiopathy in 2 participants. Terminated before completion.
3 April 2023
Quick facts
| Lead sponsor | Leiden University Medical Center |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 2 |
| Start date | 3 April 2022 |
| Primary completion | 3 April 2023 |
| Estimated completion | 3 April 2023 |
| Sites | 1 location across Netherlands |
Conditions studied
- Cerebral Amyloid Angiopathy — all drugs for Cerebral Amyloid Angiopathy →
- Intracerebral Hemorrhage — all drugs for Intracerebral Hemorrhage →
- Hypertensive Hemorrhage, Intracranial — all drugs for Hypertensive Hemorrhage, Intracranial →
- Cognitive Decline — all drugs for Cognitive Decline →
Sponsor
Leiden University Medical Center
Who can join
55 and older, any sex, with Cerebral Amyloid Angiopathy or Intracerebral Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall aim of this pilot study is to investigate the development of magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) markers after cerebral amyloid angiopathy (CAA)-related and hypertensive arteriopathy (HA)-related intracerebral hemorrhage (ICH) in relation to cognitive decline. The results from this pilot trial will be used to design a larger cohort study to investigate underlying mechanisms of cognitive decline after ICH. The study population consists of 32 patients; 16 patients with CAA-related ICH and 16 patients with HA-related ICH who are 55 years or older. Data will be collected at four measuring points: at baseline (during hospital admission for the ICH or at the outpatients clinic within one month of presentation with an acute ICH), after three months, after six months and after 12 months. Premorbid cognitive functioning will be assessed with the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) to select participants without pre-existing cognitive impairment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05499169
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebral Amyloid Angiopathy
Currently open trials in the same condition.
- NCT06933212 — Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. · recruiting
- NCT06393712 — A Phase 2 Trial of ALN-APP in Patients With Cerebral Amyloid Angiopathy · Phase 2 · recruiting
- NCT05734378 — Prognosis of Cerebral Small Vessel Disease · recruiting
- NCT04204642 — SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) · recruiting
- NCT06128824 — High Frequency Imaging in Cerebral Amyloid Angiopathy · active not recruiting
Other Leiden University Medical Center trials
Trials by the same sponsor.
- NCT07312565 — Occurrence of Abdominal Aortic Aneurysms in Patients With Aneurysmal Subarachnoid Hemorrhage · not yet recruiting
- NCT07090343 — Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement · Phase 3 · not yet recruiting
- NCT07498738 — Making Diabetes Care Fit for Young Adults Living With Type 1 Diabetes: Observations, Reflections and Expert Opinions · NA · not yet recruiting
- NCT06545292 — Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients · NA · recruiting
- NCT07021495 — SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05499169 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Leiden University Medical Center
- Last refreshed: 18 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05499169.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing